Manager Accounting
Vaxcyte
Manager Accounting
Vaxcyte
Develops broad-spectrum vaccines for bacterial infections
Summary:
The Manager Accounting , Inventory and Operations role will help manage Vaxcyte’s cost accounting functions, including standard costing, inventory valuation, and manufacturing variance analysis. This role also owns the full manufacturing accrual process for the Manufacturing Accounting Team — maintaining accrual trackers, preparing monthly accrual journal entries, reconciling manufacturing general ledger accounts, and preparing manufacturing flux analysis. The Manager Accounting Inventory and Operations role partners closely with Supply Chain and FP&A to ensure accurate cost data, drive margin improvement initiatives, and maintain strong internal controls over inventory and cost of goods sold (COGS). The ideal candidate combines strong technical accounting skills with the ability to translate cost data into actionable business insights.
Essential Functions:
Requirements:
Equal Opportunity
We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.
Recruitment Fraud Notice
Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at vaxcyte.com/careers.
Vaxcyte develops vaccines to prevent bacterial infections, focusing on broad-spectrum pneumococcal vaccines and other targets like Group A Strep, periodontitis, and Shigella. Its lead product, VAX-24, covers 24 Streptococcus pneumoniae strains and is produced using the XpressCF cell-free protein synthesis platform, which enables multi-strain conjugate vaccines. The company differentiates itself by combining cell-free manufacturing with broad strain coverage and has FDA Breakthrough Therapy designation for VAX-24, helping speed development. Its goal is to bring broadly protective bacterial vaccines to market, reduce serious infections worldwide, and expand its portfolio with products like VAX-31 and additional preclinical candidates.
Explore more opportunities at Vaxcyte